D-type cyclins, including Cyclin D1, D2, and D3, are regulators of the Cyclin-dependent kinases 4 and 6 (Cdk4 and Cdk6) and mediate the growth factor-induced progression through the G1 phase in the cell cycle. Cyclins D1 and D3 are involved in cell-cycle progression in CDK-dependent manner and CDK-independent activation of transcription as well as metabolic control. CDKs promote cell cycle transitions in mammalian cells by phosphorylating key substrates cyclins. The active complex of cyclin D/CDK4 targets the retinoblastoma protein, which triggers the release of E2F transcription factors and activates G1/S-phase gene expression. Abnormal expression of cyclins is involved in disease progression. Cyclin D3 is widely expressed in many tumor cells. Cyclin D3 gene is amplified in bladder carcinoma in situ. Genomic changes disrupting the expression of Cyclin D3 are associated with aberrant growth of several human B-lymphoid malignancies. Targeting Cyclin D3 by miR-138 could induce cell cycle arrest in hepatocellular carcinoma. Cyclin D3 was upregulated in breast cancer and could serve as predictor of breast cancer prognosis. Cyclin D3 can also be targeted in autoimmune diabetes and exerts a protective role on β cells by promoting their survival and fitness without affecting proliferation.

PRODUCT DETAILS

Clone: DCS-22

Antibody Type: Monoclonal

Reactivity: Human, Mouse, Rat

Format: PE

Host: Mouse

Isotype: IgG1, κ

Applications: ICFC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.